It is therefore tempting to speculate that radiation therapy and dsDNA damage repair antagonist drugs, such as PARP inhibitors, might be additional therapeutic options beyond PI3K pathway inhibitors for cancer in patients with PHTS carrying PTEN-R173-like variants. The gene discussed is PTEN; the disease is cancer.